Scientists investigated newly emerging mutations in circulating tumor DNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations.
[International Journal of Cancer]
